Gilead Sciences GILD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.22B+54.5% | $8.51B+1,673% | $8.11B+7,014% | $6.31B+511% | $5.97B+1,202% | ||
| $903M+5.4% | $894M+7.1% | $886M+8.8% | $872M+9.0% | $857M+8.8% | ||
| —— | —— | -$97M+94.7% | -$1.33B-0.4% | -$1.32B+4.5% | ||
| —— | —— | $474M+265% | -$21M-104% | -$284M— | ||
| $865M+43.2% | $1.04B+143% | $1.14B+125% | $709M+40.7% | $604M-8.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $706M+488% | $47M+161% | $39M-95.3% | ||
| -$1.59B— | -$2.11B— | —— | —— | —— | ||
| $10.81B+4.2% | $10.02B-7.5% | $9.67B-3.5% | $9.87B+32.1% | $10.37B+22.2% | ||
| $576M+10.3% | $563M+7.6% | $505M-14.6% | $499M-12.8% | $522M-10.2% | ||
| $906M-15.3% | $1.07B-77.9% | $536M-89.4% | $939M-79.4% | $1.07B-77.0% | ||
| $4.18B— | $3.65B— | —— | —— | —— | ||
| -$2.61B-57.4% | -$4.79B-39.0% | -$3.18B+19.4% | -$3.47B+0.1% | -$1.66B+54.6% | ||
| $4.03B+2.4% | $4B+2.2% | $3.98B+2.4% | $3.96B+2.6% | $3.94B+2.8% | ||
| $1.61B+8.9% | $1.92B+67.1% | $2.04B+115% | $1.91B+101% | $1.48B+48.0% | ||
| $322M-39.0% | $408M-3.3% | $549M+99.6% | $550M+112% | $528M+87.9% | ||
| -$8.56B— | -$7.75B— | —— | —— | —— | ||
| $67M+2,333% | $97M+343% | $37M-28.8% | $81M— | -$3M— | ||
| —— | —— | —— | $2.37B+181% | $3.21B+1,572% | ||
| $2.39B-0.1% | $2.39B+0.2% | $2.39B+0.3% | $2.39B+0.2% | $2.39B0.0% | ||
| $366M-4.7% | $370M-2.9% | $375M-0.5% | $379M+2.7% | $384M+8.5% | ||
| $318M+51.4% | $311M+20.1% | $421M— | $110M— | $210M— | ||
| -$572M-76.0% | -$480M-36.0% | -$272M+68.4% | -$269M+67.6% | -$325M+63.2% | ||
| $877M+10.2% | $1.02B-78.1% | $484M-90.4% | $819M-82.2% | $796M-83.4% | ||
| —— | —— | —— | —— | -$30M-233% | ||
| $136M+38.8% | $133M-73.0% | $158M-76.7% | $85M-87.8% | $98M-86.5% | ||
| $91M— | $55M— | —— | —— | —— | ||
| $3.37B— | $854M— | —— | —— | —— | ||
| -$443M-29.9% | -$440M-56.6% | -$424M-58.2% | -$369M-39.8% | -$341M-31.2% | ||
| $2.79B-25.2% | $1.79B-9.2% | $1.79B-9.0% | $1.89B-53.9% | $3.73B+65.9% | ||
| $10.23B+3.9% | $9.46B-8.2% | $9.16B-2.9% | $9.37B+35.9% | $9.84B+24.6% | ||
| $10.23B+3.9% | $9.46B-8.2% | $9.16B-2.9% | $9.37B+35.9% | $9.84B+24.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gilead Sciences generate?
- Gilead Sciences (GILD) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Gilead Sciences's free cash flow?
- After $576.0M of capital expenditures, Gilead Sciences's free cash flow was $10.2B over the trailing twelve months, up 3.9% year over year.
- Where does Gilead Sciences's cash flow data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
